169 related articles for article (PubMed ID: 34330885)
1. Clinical Benefit of Therapeutic Drug Monitoring in Colorectal Cancer Patients Who Received Fluorouracil-Based Chemotherapy.
Zhou X; Chang Y; Qian J; Shen C; Han J; Zhao H; Chang R
Med Sci Monit; 2021 Jul; 27():e929474. PubMed ID: 34330885
[TBL] [Abstract][Full Text] [Related]
2. Prospective, Multicenter Study of 5-Fluorouracil Therapeutic Drug Monitoring in Metastatic Colorectal Cancer Treated in Routine Clinical Practice.
Wilhelm M; Mueller L; Miller MC; Link K; Holdenrieder S; Bertsch T; Kunzmann V; Stoetzer OJ; Suttmann I; Braess J; Birkmann J; Roessler M; Moritz B; Kraff S; Salamone SJ; Jaehde U
Clin Colorectal Cancer; 2016 Dec; 15(4):381-388. PubMed ID: 27256667
[TBL] [Abstract][Full Text] [Related]
3. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer.
Gamelin E; Delva R; Jacob J; Merrouche Y; Raoul JL; Pezet D; Dorval E; Piot G; Morel A; Boisdron-Celle M
J Clin Oncol; 2008 May; 26(13):2099-105. PubMed ID: 18445839
[TBL] [Abstract][Full Text] [Related]
4. A retrospective analysis of plasma concentration monitoring of fluorouracil in patients with advanced colorectal cancer.
Yang Q; Bi Y; Li X; Liu Q; Ma J; Zhang C; Zhang J; He G
Eur J Hosp Pharm; 2020 Mar; 27(e1):e36-e40. PubMed ID: 32296503
[TBL] [Abstract][Full Text] [Related]
5. Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens.
Kline CL; Schiccitano A; Zhu J; Beachler C; Sheikh H; Harvey HA; Mackley HB; McKenna K; Staveley-O'Carroll K; Poritz L; Messaris E; Stewart D; Sivik J; El-Deiry WS
Clin Colorectal Cancer; 2014 Jun; 13(2):119-26. PubMed ID: 24461492
[TBL] [Abstract][Full Text] [Related]
6. Determining the optimal 5-FU therapeutic dosage in the treatment of colorectal cancer patients.
Fang L; Jiang Y; Yang Y; Zheng Y; Zheng J; Jiang H; Zhang S; Lin L; Zheng J; Zhang S; Zhuang X
Oncotarget; 2016 Dec; 7(49):81880-81887. PubMed ID: 27636992
[TBL] [Abstract][Full Text] [Related]
7. Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study.
Capitain O; Asevoaia A; Boisdron-Celle M; Poirier AL; Morel A; Gamelin E
Clin Colorectal Cancer; 2012 Dec; 11(4):263-7. PubMed ID: 22683364
[TBL] [Abstract][Full Text] [Related]
8. Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6.
Kaldate RR; Haregewoin A; Grier CE; Hamilton SA; McLeod HL
Oncologist; 2012; 17(3):296-302. PubMed ID: 22382460
[TBL] [Abstract][Full Text] [Related]
9. How can we best monitor 5-FU administration to maximize benefit to risk ratio?
Goirand F; Lemaitre F; Launay M; Tron C; Chatelut E; Boyer JC; Bardou M; Schmitt A
Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1303-1313. PubMed ID: 30451549
[TBL] [Abstract][Full Text] [Related]
10. The role of IVS14+1 G > A genotype detection in the dihydropyrimidine dehydrogenase gene and pharmacokinetic monitoring of 5-fluorouracil in the individualized adjustment of 5-fluorouracil for patients with local advanced and metastatic colorectal cancer: a preliminary report.
Cai X; Fang JM; Xue P; Song WF; Hu J; Gu HL; Yang HY; Wang LW
Eur Rev Med Pharmacol Sci; 2014; 18(8):1247-58. PubMed ID: 24817302
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic drug monitoring of 5-fluorouracil.
Lee JJ; Beumer JH; Chu E
Cancer Chemother Pharmacol; 2016 Sep; 78(3):447-64. PubMed ID: 27217046
[TBL] [Abstract][Full Text] [Related]
12. Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients.
Kline CL; Sheikh HS; Scicchitano A; Gingrich R; Beachler C; Finnberg NK; Liao J; Sivik J; El-Deiry WS
Cancer Biol Ther; 2011 Oct; 12(7):557-68. PubMed ID: 21931273
[TBL] [Abstract][Full Text] [Related]
13. Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers.
Ho YF; Lu WC; Chen RR; Cheng AL; Yeh KH
Anticancer Drugs; 2011 Mar; 22(3):290-8. PubMed ID: 21150775
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM™ system in a quaternary oncology centre.
Moloney M; Faulkner D; Link E; Rischin D; Solomon B; Lim AM; Zalcberg JR; Jefford M; Michael M
Cancer Chemother Pharmacol; 2018 Nov; 82(5):865-876. PubMed ID: 30178115
[TBL] [Abstract][Full Text] [Related]
15. A community-based multicenter trial of pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal cancer therapy.
Patel JN; O'Neil BH; Deal AM; Ibrahim JG; Sherrill GB; Olajide OA; Atluri PM; Inzerillo JJ; Chay CH; McLeod HL; Walko CM
Oncologist; 2014 Sep; 19(9):959-65. PubMed ID: 25117066
[TBL] [Abstract][Full Text] [Related]
16. LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients.
Büchel B; Rhyn P; Schürch S; Bühr C; Amstutz U; Largiadèr CR
Biomed Chromatogr; 2013 Jan; 27(1):7-16. PubMed ID: 22454320
[TBL] [Abstract][Full Text] [Related]
17. Drug monitoring detects under- and overdosing in patients receiving 5-fluorouracil-containing chemotherapy-results of a prospective, multicenter German observational study.
Li M; Mindt S; Lück A; Hutzschenreuter U; Kollendt M; Lathan B; Zöller T; Frank-Gleich S; Lorentz C; Lamberti C; Sick C; Zingerle M; Tesch H; Stein W; Hebart H; Stosiek C; Sandner R; Fries S; Burkholder I; Hofheinz RD
ESMO Open; 2023 Apr; 8(2):101201. PubMed ID: 36965262
[TBL] [Abstract][Full Text] [Related]
18. Individual 5-Fluorouracil Dose Adjustment via Pharmacokinetic Monitoring Versus Conventional Body-Area-Surface Method: A Meta-Analysis.
Yang R; Zhang Y; Zhou H; Zhang P; Yang P; Tong Q; Lyu Y; Han Y
Ther Drug Monit; 2016 Feb; 38(1):79-86. PubMed ID: 26309030
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic dose adjustment of 5-FU in modified FOLFOX7 plus bevacizumab for metastatic colorectal cancer in Japanese patients: a-JUST phase II clinical trial.
Denda T; Kanda M; Morita Y; Kim HM; Kashiwada T; Matsuda C; Fujieda S; Nakata K; Murotani K; Oba K; Sakamoto J; Mishima H
Cancer Chemother Pharmacol; 2016 Dec; 78(6):1253-1261. PubMed ID: 27807652
[TBL] [Abstract][Full Text] [Related]
20. Will we ever be ready for blood level-guided therapy?
Walko CM; McLeod HL
J Clin Oncol; 2008 May; 26(13):2078-9. PubMed ID: 18445837
[No Abstract] [Full Text] [Related]
[Next] [New Search]
